Antibody-based identification of cell surface antigens: targets for cancer therapy

Curr Opin Pharmacol. 2008 Oct;8(5):627-31. doi: 10.1016/j.coph.2008.08.011. Epub 2008 Oct 4.


The identification of novel cell surface antigens present on tumor cells is crucial for developing new cancer therapies. Intact, viable cancer cells, which display cancer-restricted antigens in their native conformation and cellular context, provide a rich source of novel antigens. Antibody-based technologies are being used to probe the surface of intact cancer cells for cancer-specific antigen targets. In addition to identifying new proteins, these approaches are generating monoclonal antibodies (MAbs) to cancer-specific epitopes and nonprotein targets not amenable to genomics-based approaches. The multiple cell-based approaches developing epitope-specific MAbs to cancer antigens is likely to usher in a new era of therapeutic MAb target discovery.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies* / chemistry
  • Antigens, Surface / chemistry
  • Antigens, Surface / drug effects*
  • Antigens, Surface / immunology*
  • Antineoplastic Agents / pharmacology*
  • Genomics
  • Humans
  • Proteomics


  • Antibodies
  • Antigens, Surface
  • Antineoplastic Agents